Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.
Transcript
How will CMS’ proposal to ease restrictions on how Part D manages the 6 protected classes of drugs impact community oncologists and their patients?
Step edits in general are becoming very onerous. We have to hire staff, we have to have extra inventory, and we follow clinical guidelines, so we’re doing evidence-based medicine. So, they have to jump through these extra hoops and have other people tell us how care should be delivered is really onerous. We are not a fan of step edits in general, and not having excluded classes in Part D that were previously were, we’re not fans.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Exploring Consumer Perspectives on Network Adequacy Definitions
September 19th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the September 2024 issue of The American Journal of Managed Care® that explored the factors consumers consider essential for an adequate provider network.
Listen